BMS Chooses ICON as Provider for Clinical Services

Under the agreement, ICON will become a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

Irish clinical development service provider ICON has been selected by Bristol-Myers Squibb as a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

ICON also provides global support for BMS’ clinical development pipeline, per the companies' June 2010 agreement.

Under the preferred provider agreement, ICON will provide a broad range of early phase services from its Clinical Pharmacology Units in San Antonio, TX, Omaha, NE, and Manchester, UK, as well as scientific services such as protocol design and development, project management, clinical monitoring, medical monitoring/pharmacovigilence, data management, biostatistics, pharmacokinetics and medical writing.